Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-05-25 AGM Information
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 25 MAI 2023
AGM Information Classification · 99% confidence The document is titled "DESCRIPTIF DU PROGRAMME DE RACHAT D'ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 25 MAI 2023" (Description of the Share Buyback Program Authorized by the Ordinary General Meeting of May 25, 2023). It details the objectives, maximum price, number of shares, and duration of a share repurchase program authorized by the shareholders. This directly relates to the company's capital structure management and transactions involving its own shares, which is explicitly covered by the 'Transaction in Own Shares' definition (POS). Although it mentions the AGM authorization, the core content is the detailed plan for share repurchases, making POS the most accurate classification over AGM-R.
2023-05-25 French
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023
AGM Information Classification · 99% confidence The document is titled "DESCRIPTION OF THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 25 MAY 2023" and details the objectives, maximum price, duration, and allocation of treasury shares related to a share repurchase program. This directly relates to the company buying back or selling its own shares. The filing type definition for 'Transaction in Own Shares' (POS) is 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although it references an AGM resolution, the core content is the description of the repurchase plan itself, not the AGM materials (AGM-R) or the voting results (DVA). It is a detailed report on the share repurchase activity.
2023-05-25 English
Inventiva publie ses informations financières du 1er trimestre 2023¹ et fait un point sur ses activités
Earnings Release Classification · 98% confidence The document is titled "Inventiva publie ses informations financières du 1er trimestre 2023 et fait un point sur ses activités" (Inventiva publishes its first quarter 2023 financial information and provides an update on its activities). It explicitly details the cash position as of March 31, 2023 (Q1), reports on operating cash flow consumption for Q1 2023, and mentions zero revenue for the quarter. It also provides a detailed update on R&D progress and future milestones. This structure—financial highlights for a specific interim period (Q1) combined with operational updates—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses on key financial highlights (cash, revenue summary) and operational updates rather than being a comprehensive, detailed financial statement (which would lean towards IR), and it is explicitly presented as a press release announcing these results, the most appropriate classification is Earnings Release (ER). The length (over 20,000 characters) suggests it is more than just a brief announcement, but the content is structured as the initial release of period results. Q1 2023
2023-05-16 French
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
Earnings Release Classification · 99% confidence The document is explicitly titled "Inventiva reports 2023 First Quarter Financial Information and provides a corporate update" and contains detailed sections on 'Financial Results' including cash position (€56.3 million as of March 31, 2023) and R&D expenses for the first quarter. It also provides an outlook for the next reporting period ("Financial results, cash position and revenues, for the first half of 2023: Thursday, July 27, 2023"). This structure—reporting on a specific fiscal period shorter than a year (Q1) with comprehensive financial details and operational updates—is characteristic of an Interim/Quarterly Report. It is more detailed than a simple Earnings Release (ER) but is not the full Annual Report (10-K). Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2023-05-16 English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 17 avril 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social au 17 avril 2023" (Information relative to the total number of voting rights and shares comprising the share capital as of April 17, 2023). It explicitly details the number of shares outstanding and the gross/net voting rights as of a specific date, referencing the French Commercial Code (Article R. 22-10-23) and AMF regulations. This type of mandatory periodic disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure updates or pre-AGM/EGM disclosures. Since it is a formal, dated announcement about the capital structure and voting rights calculation basis, it fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). However, given the specific focus on the total number of shares and voting rights, which is a key component of capital structure reporting, CAP is a strong candidate. It is not a full Annual Report (10-K), Earnings Release (ER), or a Dividend Notice (DIV). It is a formal regulatory disclosure about the share capital count, which aligns closely with 'Capital/Financing Update' (CAP) or a general regulatory announcement. Since the core content is the official count of shares and voting rights, which directly impacts capital structure, I will classify it as CAP, although RNS is a close secondary option if CAP were strictly limited to fundraising activities. Given the context of French regulatory filings, this is a standard 'information mensuelle sur le nombre d'actions et de droits de vote'. I will select CAP as it relates directly to the capital structure components.
2023-05-04 French
Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is a 'Statement of total voting rights and shares forming the company's share capital as of April 17, 2023'. It provides a table detailing the number of outstanding shares and total voting rights (gross and net) as of that specific date, referencing French Commercial Code articles related to voting rights disclosure. This content directly corresponds to regulatory requirements for disclosing share capital structure and voting power, which is often disclosed via a specific regulatory filing or announcement related to share capital changes or voting rights updates. The document is structured like a formal regulatory disclosure, not a general press release, earnings report, or management discussion. The closest specific category is related to capital structure or voting rights. Since it is a formal statement of voting rights and share capital, it aligns best with a specific regulatory disclosure concerning share structure, which is often captured under general regulatory filings or specific capital/share announcements. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most precise fit, as the core content is the total voting rights calculation. It is not a general announcement of a dividend (DIV) or a general share issue (SHA), but a mandatory statement of the current voting rights status.
2023-05-04 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.